Coming Soon

RRP-331: Ph3, randomized, placebo-controlled, blinded trial of INO-3107 w/electroporation (EP) and/or recurrent respiratory papillomatosis (RRP)

The purpose of this research is to determine if an investigational drug, INO-3107, administered with an investigational device, is tolerable in patients with recurrent respiratory papillomatosis (RRP) and helps reduce future surgical procedures.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Sid Sheth
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Head and Neck)
Lungs and Breathing

IRB Number

24-1692

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.